此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. (CPI)

2026年9月11日 更新者:Centre Antoine Lacassagne
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) not amenable to curative local treatment.

研究概览

研究类型

介入性

注册 (估计的)

110

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

- Patients over 18 years of age

- Patients diagnosed with :

  1. Non-small cell lung cancer (NSCLC), including adenocarcinoma and squamous cell carcinoma.
  2. Head and neck squamous cell carcinoma, p16-negative for oropharyngeal tumors.

    • Recurrent and/or metastatic tumor not amenable to curative locoregional treatment.
    • Disease progression under Pembrolizumab immunotherapy, administered at the standard dose of 200 mg every 3 weeks, as first-line treatment for metastatic disease, regardless of the number of cycles received, either as monotherapy or in combination with chemotherapy, as defined below:

      • For pulmonary adenocarcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) and Pemetrexed

    ii. Maintenance therapy with Pembrolizumab, with or without Pemetrexed.

    • For pulmonary squamous cell carcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin) and Paclitaxel

    +/- ii. Maintenance therapy with Pembrolizumab alone.

    • For head and neck squamous cell carcinomas : i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) ± 5-Fluorouracil (5-FU) or Paclitaxel

    +/- ii. Maintenance therapy with Pembrolizumab alone.

    • Eligibility for salvage chemotherapy within standard care:

      • For pulmonary adenocarcinomas: weekly Paclitaxel, with or without Bevacizumab.

      • For pulmonary squamous cell carcinomas: Gemcitabine monotherapy.
      • For head and neck squamous cell carcinomas: weekly Paclitaxel and/or Cetuximab. Standard salvage chemotherapy may be initiated between Day 18 and Day 35 following the last Pembrolizumab injection, at standard doses.
    • Measurable disease according to RECIST 1.1 criteria.
    • Performance status (PS) 0 to 2.
    • Baseline laboratory results meeting the usual criteria permitting initiation of salvage chemotherapy.
    • Patients who has voluntarily agreed to participate in the study (including additional blood sampling) and has signed the informed consent form.
    • For the subpopulation with accessible tissue biopsy:

      • Patient agrees to undergo biopsy,
      • INR < 1.5, Platelets > 50000/μL.
    • Patients covered by a social security health insurance scheme.

    Exclusion Criteria:

    • History of cancer, except for cancers in complete remission for more than 3 years, fully resected cutaneous basal cell carcinomas, or treated carcinoma in situ or cervical intraepithelial neoplasia (in situ cervical epithelioma),
    • Patients participating in another clinical trial for which an exclusion period is specified,
    • Minor patients,
    • For the subpopulation with accessible tissue biopsy, patients receiving:

      • Clopidogrel (hydrogen sulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) without the possibility of discontinuation for 5 days,

      • Low-molecular-weight heparin (LMWH) without the possibility of dose suspension prior to the procedure,

      • Or Fondaparinux without the possibility of discontinuation,

      • Or Abciximab without the possibility of discontinuation for 24 hours and aPTT < 50s and ACT < 150s,

      • Or Eptifibatide or Tirofiban hydrochloride monohydrate or Argatroban without the possibility of discontinuation 4 hours before the procedure,

      • Or Bivalirudin without the possibility of discontinuation 2-3 hours before the procedure if CrCL > 50 mL/min, or 3-5 hours if CrCL < 50 mL/min,
      • Or Dabigatran etexilate without the possibility of discontinuation 2-3 days before the procedure if CrCL > 50 mL/min, or 3-5 days if CrCL < 50 mL/min.
    • Vulnerable persons as defined in Articles L1121-5 to L1121-8 :

      • Pregnant women, women in labour, and breastfeeding mothers,

      • Persons deprived of liberty by judicial or administrative decision, and persons hospitalized without consent under Articles L3212-1 and L3213-1 who do not fall under the provisions of Article L1121-8,
      • Persons admitted to a health or social care institution for purposes other than research,
      • Adults under legal protection measures or unable to express their consent.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Residual Pembrolizumab Exposure Assessment
Patients will be followed according to standard clinical care. Biological samples collected include: (1) pharmacokinetic and extracellular vesicle analyses: 10 mL blood samples in EDTA tubes at 21±3, 35±3, 49±3, and 63±3 days after the last pembrolizumab administration (P1-P4); (2) pharmacogenetic analysis: one baseline 5 mL EDTA blood sample; (3) cytokine and immune cell analyses: at P1 and P4, collection of 2×4 mL lithium heparin tubes, 1×10 mL EDTA tube, and 1×5 mL dry tube.

Depending on feasibility of the procedure, and at the discretion of the investigator, two biopsies will be performed in 20 consenting patients:

  • Biopsy B1: between the last administration of pembrolizumab (Day 0) and before initiation of standard salvage chemotherapy,
  • Biopsy B2: after initiation of salvage chemotherapy, at Day 63 ± 7 days after the last administration of pembrolizumab. If chemotherapy is discontinued prematurely, Biopsy B2 may only be performed if the patient has received at least 3 weeks of chemotherapy exposure.

Due to logistical constraints, these biopsies will be proposed to patients followed at CAL. They will be performed primarily in the interventional radiology department of CAL.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective response rate (ORR) at 3 months after initiation of salvage chemotherapy (RECIST v1.1)
大体时间:3 months after initiation of salvage chemotherapy

Objective response rate (ORR) includes the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria.

Tumor response will be assessed using routine imaging performed during standard clinical follow-up care.

ORR will be analyzed in relation to residual pembrolizumab (anti-PD-1) serum concentration measured 21 days after the last administration of pembrolizumab (P1), immediately prior to initiation of salvage chemotherapy.

3 months after initiation of salvage chemotherapy

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2029年5月1日

研究完成 (估计的)

2029年5月1日

研究注册日期

首次提交

2026年5月29日

首先提交符合 QC 标准的

2026年6月4日

首次发布 (实际的)

2026年6月8日

研究记录更新

最后更新发布 (实际的)

2026年9月15日

上次提交的符合 QC 标准的更新

2026年9月11日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅